Citigroup
ACRV icon

Citigroup’s Acrivon Therapeutics ACRV Stock Holding History

Citigroup’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.57K Buy
2,715
+2,709
+45,150% +$5.15K ﹤0.01% 5339
2026
Q2 		$11 Buy
+6
New +$10 ﹤0.01% 5593
2026
Q1 		– Sell
-14,592
Closed -$35.2K – 5897
2025
Q4 		$35.2K Sell
14,592
-1,713
-11% -$3.72K ﹤0.01% 4691
2025
Q3 		$29.5K Sell
16,305
-16,077
-50% -$22.6K ﹤0.01% 4668
2025
Q2 		$38.5K Buy
32,382
+21,223
+190% +$29.1K ﹤0.01% 4891
2025
Q1 		$22.7K Sell
11,159
-1,173
-10% -$6.32K ﹤0.01% 5061
2024
Q4 		$74.2K Buy
12,332
+1,116
+10% +$8.11K ﹤0.01% 4959
2024
Q3 		$78.5K Buy
11,216
+6,134
+121% +$48.3K ﹤0.01% 4873
2024
Q2 		$29.5K Buy
5,082
+546
+12% +$4.4K ﹤0.01% 4873
2024
Q1 		$32.4K Buy
4,536
+2,489
+122% +$11.6K ﹤0.01% 4861
2023
Q4 		$10.1K Buy
2,047
+1,817
+790% +$9.6K ﹤0.01% 5194
2023
Q3 		$2.2K Sell
230
-2,560
-92% -$29.6K ﹤0.01% 4938
2023
Q2 		$36.2K Buy
2,790
+2,588
+1,281% +$31.3K ﹤0.01% 4793
2023
Q1 		$2.56K Buy
+202
New +$3.39K ﹤0.01% 5061

Other funds holding ACRV

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
AAF Wealth Management
AAF Wealth Management Westborough, Massachusetts $275M AUM 17.17% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Redwood Park Advisors
Redwood Park Advisors Redwood City, California $157M AUM 7.34% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Citigroup's ACRV Position: Q3 2026 in Review

Citigroup increased its Acrivon Therapeutics (ACRV) stake by 45,150% in Q3 2026, buying an estimated $5.15K and bringing the position to 2,715 shares worth $5.57K. The position accounts for ﹤0.01% of the portfolio, ranked #5339.

Citigroup first reported a position in ACRV in Q1 2023 and has held it in 14 quarters since. The position peaked at $78.5K in Q3 2024. 11 funds tracked by Wall St. Rank hold ACRV as of Q3 2026.

  • Citigroup held 2,715 shares of Acrivon Therapeutics worth $5.57K as of Q3 2026.
  • Citigroup bought 2,709 Acrivon Therapeutics shares in Q3 2026, an estimated $5.15K.
  • Acrivon Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5339 holding.
  • Citigroup first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Citigroup's Acrivon Therapeutics position peaked at $78.5K in Q3 2024.
  • 11 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.